Elena Santagostino

List of Publications by Year
in descending order

55 papers	4,229 citations	279798 23 h-index	161849 54 g-index
55 all docs	55 docs citations	55 times ranked	2268 citing authors

#	Article	IF	Citations
1	WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia, 2020, 26, 1-158.	2.1	915
2	Emicizumab Prophylaxis in Hemophilia A with Inhibitors. New England Journal of Medicine, 2017, 377, 809-818.	27.0	794
3	A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. New England Journal of Medicine, 2016, 374, 2054-2064.	27.0	414
4	Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood, 2013, 122, 1954-1962.	1.4	188
5	Development and definition of a simplified scanning procedure and scoring method for Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US). Thrombosis and Haemostasis, 2013, 109, 1170-1179.	3.4	188
6	How I treat age-related morbidities in elderly persons with hemophilia. Blood, 2009, 114, 5256-5263.	1.4	175
7	Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood, 2016, 127, 1761-1769.	1.4	168
8	Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood, 2012, 120, 2405-2411.	1.4	160
9	Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A. Thrombosis and Haemostasis, 2017, 117, 252-261.	3.4	96
10	Practical aspects of extended half-life products for the treatment of haemophilia. Therapeutic Advances in Hematology, 2018, 9, 295-308.	2.5	85
11	The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab. Haemophilia, 2019, 25, 676-684.	2.1	75
12	Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A. Blood, 2019, 134, 317-320.	1.4	71
13	Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates. Journal of Clinical Medicine, 2017, 6, 39.	2.4	70
14	Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. Blood, 2016, 128, 630-637.	1.4	69
15	The effect of emicizumab prophylaxis on healthâ€related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia, 2019, 25, 33-44.	2.1	63
16	Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis. Blood Reviews, 2019, 35, 43-50.	5.7	57
17	Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigmâ„¢4). Thrombosis Research, 2016, 141, 69-76.	1.7	52
18	Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfusion, 2014, 12, 575-98.	0.4	52

#	Article	IF	Citations
19	Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Thrombosis and Haemostasis, 2016, 116, 659-668.	3.4	50
20	Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management. Blood Transfusion, 2015, 13, 498-513.	0.4	48
21	Innovative Pharmacological Therapies for the Hemophilias Not Based on Deficient Factor Replacement. Seminars in Thrombosis and Hemostasis, 2016, 42, 526-532.	2.7	32
22	Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement. Haematologica, 2019, 104, e380-e382.	3.5	30
23	Longâ€term safety and efficacy of rIXâ€FP prophylaxis with extended dosing intervals up to 21Âdays in adults/adolescents with hemophilia B. Journal of Thrombosis and Haemostasis, 2020, 18, 1065-1074.	3.8	26
24	PROLONG-9FP clinical development program â€“ phase I results of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP). Thrombosis Research, 2013, 131, S7-S10.	1.7	25
25	Desmopressin in moderate hemophilia A patients: a treatment worth considering. Haematologica, 2018, 103, 550-557.	3.5	23
26	Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Blood Transfusion, 2020, 18, 143-151.	0.4	22
27	Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital haemophilia with inhibitors. Blood Reviews, 2015, 29, S9-S18.	5.7	21
28	Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial. Thrombosis Research, 2019, 183, 13-19.	1.7	21
29	PROTECT VIII Kids: BAY 94â€9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A. Haemophilia, 2020, 26, e55-e65.	2.1	20
30	Major surgery management in patients with haemophilia A and inhibitors on emicizumab prophylaxis without global coagulation monitoring. British Journal of Haematology, 2020, 189, e100-e103.	2.5	18
31	Invasive procedures in patients with haemophilia: Review of lowâ€dose protocols and experience with extended halfâ€life FVIII and FIX concentrates and nonâ€replacement therapies. Haemophilia, 2021, 27, 46-52.	2.1	18
32	The importance of inhibitor eradication in clinically complicated hemophilia A patients. Expert Review of Hematology, 2018, 11, 857-862.	2.2	16
33	High adherence to prophylaxis regimens in haemophilia B patients receiving rIXâ€FP: Evidence from clinical trials and realâ€world practice. Haemophilia, 2020, 26, 637-642.	2.1	16
34	Longâ€term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial. Haemophilia, 2018, 24, e391-e394.	2.1	15
35	Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP. Journal of Medical Economics, 2019, 22, 1014-1021.	2.1	15
36	Practical considerations for nonfactorâ€replacement therapies in the treatment of haemophilia with inhibitors. Haemophilia, 2021, 27, 340-350.	2.1	15

#	Article	IF	Citations
37	Treatment Regimens with Bypassing Agents in Patients with Hemophilia A and Inhibitors: A Survey from the Italian Association of Hemophilia Centers (AICE). Seminars in Thrombosis and Hemostasis, 2018, 44, 551-560.	2.7	12
38	Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials. Haemophilia, 2020, 26, 450-458.	2.1	11
39	Position paper on laboratory testing for patients with haemophilia. A consensus document from SISET, AICE, SIBioC and SIPMeL. Blood Transfusion, 2019, 17, 229-236.	0.4	10
40	Simplifying surgery in haemophilia B: Low factor IX consumption and infrequent infusions in surgical procedures with rIX-FP. Thrombosis Research, 2020, 188, 85-89.	1.7	8
41	Rate and appropriateness of polypharmacy in older patients with hemophilia compared with ageâ€matched controls. Haemophilia, 2018, 24, 726-732.	2.1	7
42	Recombinant FVIIIFc Versus BAY 94-9027 for Treatment of Patients with HaemophiliaÂA: Comparative Efficacy Using a Matching Adjusted Indirect Comparison. Advances in Therapy, 2021, 38, 1263-1274.	2.9	7
43	rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B: Post hoc analysis of Bâ€LONG using haemophiliaâ€specific quality of life questionnaires. Haemophilia, 2021, , .	2.1	7
44	Diagnosis and treatment of chronic synovitis in patients with haemophilia: consensus statements from the Italian Association of Haemophilia Centres. British Journal of Haematology, 2022, 196, 871-883.	2.5	7
45	Beyond stopping the bleed: short-term episodic prophylaxis with recombinant activated factor FVII in haemophilia patients with inhibitors. Blood Transfusion, 2017, 15, 77-84.	0.4	6
46	GlycoPEGylated recombinant factor IX for hemophilia B in context. Drug Design, Development and Therapy, 2018, Volume 12, 2933-2943.	4.3	5
47	Target joint resolution in patients with haemophilia A receiving longâ€term prophylaxis with BAY 94â€9027. Haemophilia, 2020, 26, e201-e204.	2.1	5
48	Cognitive and psychological profiles in treatment compliance: a study in an elderly population with hemophilia. Clinical Interventions in Aging, 2015, 10, 1141.	2.9	4
49	Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company. Haemophilia, 2020, 26, 966-974.	2.1	4
50	Safety and efficacy of BAY 94â€“9027, an extendedâ€halfâ€life factor VIII, during minor surgical procedures in patients with severe haemophilia A. Haemophilia, 2021, 27, e559-e562.	2.1	4
51	BAY 81â€8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for â‰¥Âyears. European Journal of Haematology, 2020, 104, 594-601.	2.2	3
52	New data from the Italian National Register of Congenital Coagulopathies, 2016 Annual Survey. Blood Transfusion, 2020, 18, 58-66.	0.4	3
53	Safety and efficacy of nonacog alfa for the treatment of haemophilia B in children younger than 6 years of age in a routine clinical care setting: the EUREKIX registry study. Haemophilia, 2021, 27, e60-e68.	2.1	2
54	Comparison of quality of life, and emotional and functional profiles in older people with and without severe haemophilia. Haemophilia, 2021, 27, e525-e529.	2.1	1

#	Article	IF	Citations
55	Successful Use of rFVIII, Turoctocog Alfa, during Orthopedic and Nonorthopedic Surgery in Patients with Severe Hemophilia A. Blood, 2015, 126, 2304-2304.	1.4	0